Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 40-week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL in participants with type 2 diabetes inadequately controlled on oral anti diabetic drugs. COMBINE 4
This study looks at a new once-a-week insulin treatment, IcoSema, for people with type 2 diabetes whose blood sugar isn't well controlled by their current medicines. It compares IcoSema to a daily insulin, glargine, to see which is better and safer.
For: Type 2 diabetesGreece · Italy · Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec when Switching from Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults with Type 2 Diabetes
This study is looking at a new once-a-week insulin treatment, called insulin icodec, for people with type 2 diabetes. It's comparing it to a daily insulin, Lantus, to see if the weekly option is safe and works just as well to control blood sugar.
For: Type 2 DiabetesPoland · Spain · Bulgaria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insuline glargine in participants with type 2 diabetes and overweight
This study is looking at how a weekly injection called semaglutide (Ozempic) works alongside a reduced dose of insulin glargine (Lantus) in people with type 2 diabetes who are also overweight. We want to see if this combination helps manage blood sugar better.
For: Participants with T2D and overweightCzechia · Portugal · Spain - AuthorisedTherapeutic use (Phase IV)
EFFectiveness of once-weekly insulin ICodec versus once-daily basal Insulin analogues in an insulin-naïve type 2 diabEtes population in real-world cliNical pracTice- The EFFICIENT pragmatic study
This study looks at different insulin treatments for people with type 2 diabetes who are just starting insulin. It compares a new once-weekly insulin called Icodec with other daily insulins people usually take. The aim is to see how well they work in real life and how easy they are to use.
For: Type 2 diabetesGermany · Italy